Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Glucagon in Common Cold and with Decongestant
NCT02778100Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2013
- Primary completion
- Apr 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of glucagon in hypoglycemia (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Events at 30 days. Started Mar 2013; status: completed.
02
Drugs
glucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT02778100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778100.